Combination drugs before kidney cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if taking two drugs, belzutifan and pembrolizumab, before surgery can help shrink high-risk kidney cancer tumors and improve outcomes. It may be an option for people with locally advanced clear cell kidney cancer who are scheduled for nephrectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with clear cell renal cell carcinoma (a type of kidney cancer) that is high-risk and has not spread to other parts of the body.
- Your doctor has recommended surgery to remove your kidney.
- You are generally healthy (able to perform daily activities) and have adequate organ function.
- You have not had prior systemic therapy or radiation for this kidney cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial is testing a combination of two drugs, zanzalintinib and pembrolizumab, given before surgery to people with a specific type of kidney cancer (clear cell renal cell carcinoma) that can be removed. The goal is to see if this treatment helps shrink or control the cancer before surgery.
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
This trial tests whether giving an immunotherapy drug (PD-L1 inhibitor) and an oral medication (anlotinib) before surgery can help shrink complex kidney tumors so that surgeons can remove only part of the kidney, preserving more kidney function. It may help you avoid losing your whole kidney.
This trial tests whether giving two immunotherapy drugs before surgery can safely shrink kidney cancer tumors and help your body fight the cancer. You would receive the drugs before your scheduled surgery, and then your cancer would be removed as planned.
Hear when a new Locally Advanced Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.